Context: Lung impairment is a new target for late diabetic complications. Biomarkers that could help identify patients requiring functional respiratory tests have not been reported.
T he deleterious effects of type 2 diabetes (T2D) on pulmonary function have not classically been included among the chronic complications of this disease. However, lung parenchyma combines its substantial vascularization with abundant elastin and collagen fibers, thus rendering it a potential target for chronic hyperglycemia (1, 2) . In fact, epidemiological studies have described how subjects with T2D exhibited lower forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) values than healthy control populations (3) (4) (5) . In addition, fasting plasma glucose and glycated hemoglobin (HbA1c) levels have shown an inverse association with spirometric values (3, 4) .
The underlying factors contributing to the development of pulmonary dysfunction in T2D are still not fully known. However, insulin resistance, low-grade chronic inflammation, microvascular damage, and defects in the bronchiolar surfactant layer are considered the main pathogenic factors (6) (7) (8) (9) . In addition, reductions in FVC and FEV 1 have been reported in obesity, which is frequently associated with T2D, thus contributing to restrictive lung disease (10, 11) .
When the bronchiolar surfactant layer-a complex mixture composed of~90% phospholipids and four specific associated proteins and involved in maintaining airway stability and caliber-is damaged, surfactant proteins migrate from the alveolar space into the bloodstream (12) . Two hydrophilic surfactant proteins, D and A (SP-D and SP-A, respectively), have been described (13, 14) . SP-D is a large member of the collagencontaining C-type lectins. It is produced primarily by alveolar type II cells in the lung epithelium, participates in pulmonary immunity and homeostasis, and has been used to detect short-term changes in lung integrity (13) (14) (15) . On the other hand, SP-A is the major protein component of the surfactant; it regulates surfactant phospholipid synthesis, secretion, and recycling. In addition to this important role in the structure of the extracellular form of surfactant, SP-A also modulates host response to microbes and particulates at the level of the alveolus (16, 17) .
Because lung epithelium-specific proteins such as SP-D and SP-A may reflect pulmonary epithelial injury and consequent increased permeability, they have been identified as potential systemic biomarkers for lung injury in a variety of diseases, such as chronic obstructive pulmonary disease (COPD), lung cancer, and acute respiratory distress syndrome (18) (19) (20) . In addition, an inverse relationship between serum SP-D concentration and FEV 1 value has been reported, thus reinforcing the concept that serum surfactant proteins could be a useful biomarker of pulmonary function (20) (21) (22) (23) . However, it is unknown whether SP-D and SP-A could be useful for identifying patients with T2D and pulmonary damage.
Based on this evidence, we hypothesized that factors contributing to impaired airway caliber regulation in patients with T2D may be related to defects in the bronchiolar surfactant layer, favoring the escape of its proteins from the alveolar space into the vascular compartment. Therefore, we designed a case-control study aimed at examining whether circulating levels of SP-D and SP-A are increased and can be used as potential biomarkers and an alternative method for evaluating the integrity of the alveolar capillary membrane in obese subjects with T2D but no known pulmonary disease.
Materials and Methods

Ethics statement
The protocol and consent forms were approved by the Ethical Committee of the Hospital Universitari Vall d'Hebron, and an informed written consent form was obtained from each patient.
Design of the study and description of the study population
We evaluated the effect of T2D and the degree of glycemic control on serum levels of SP-D and SP-A using the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for reporting case-control studies (24) .
A total of 221 white patients with T2D attending the obesity unit of our Endocrinology Department during 2015 were examined at the time of their regular visit (Supplemental Fig. 1 ). The inclusion criteria were age .18 years, nonsmoking status, body mass index (BMI) of 30 kg/m 2 or higher, and T2D with at least 5 years of follow-up.
Using the standard deviation of serum SP-D detected in a previous study, we determined that the minimum sample size required was 44 subjects (20) . Among the 84 patients who met the inclusion criteria, we excluded 27 for the following reasons: COPD (n = 8), heart failure (n = 3), active malignancy (n = 2), a glomerular filtration rate lower than 60 mL/min/1.73 m 2 (n = 5), an age .80 years (n = 3), chronic treatment with steroids (n = 4), and pregnancy (n = 2). In addition, because the glucagonlike peptide 1 receptor is abundant in the lungs, where it could be implicated in the regulation of the lipid fraction of surfactants, we excluded eight patients receiving treatment with human glucagonlike peptide 1 receptor agonists (25) .
Therefore, a total of 49 cases were included. We aimed to select two controls for every case, and we assembled a control group consisting of 98 subjects without diabetes who were visiting the same unit at our hospital during the same period. The controls were closely matched to the cases in terms of age, sex, BMI, and waist circumference. The primary clinical characteristics and metabolic data of the study population are listed in Table 1 .
In addition, when we observed that patients with T2D exhibited substantial differences in pulmonary flow and volume measures compared with the control group, we decided to recruit a third set of 38 obese subjects without diabetes (age: 41.5 6 11.6 years; BMI: 43.8 6 7.7 kg/m 2 ; waist circumference: 130.8 6 10.2 cm; fasting plasma glucose level: 5.1 6 0.5 mmol/L; HbA1c level: 34.7 6 5.1 mmol/mol, 5.3% 6 0.4%) and without known lung disease who were matched to the cases not only by BMI and waist circumference but also by spirometric values. This approach permitted us to rule out the possibility that changes in serum surfactant proteins were related merely to the presence of lung impairment rather than to T2D. T2D was defined according to the criteria recommended by the Expert Committee on the Diagnosis and Classification of Diabetes (26) .
Treatment of T2D included diet alone (12.2%), metformin alone (22.4%), metformin plus sulfonylureas (16.3%), metformin plus basal insulin (18.3%), and basal plus or basal bolus therapy (6.1%). The remaining 11 patients (24.4%) were receiving different oral treatment combinations.
Sample collection
After patients fasted overnight for 12 hours, we collected venous blood from the antecubital vein. We separated the samples by centrifugation (3.000g at 4°C for 20 minutes), and the aliquots were stored at 280°C for batched analysis. Serum SP-D and SP-A concentrations (ng/mL) were assessed by enzyme-linked immunosorbent assay (BioVendor R&D; Deltaclon, Barcelona, Spain). The enzyme-linked immunosorbent assay was performed according to the method described by the manufacturer. The SP-D and SP-A samples were diluted 1:11 and 1:10, respectively, with the dilution buffer provided in the kit and were vortexed. The limit of SP-D detection was 0.01 ng/mL, and the assay limit was 500 ng/mL; the coefficient of variation (CV) intra-assay value was 2.1%, and the CV interassay value was 3.7%. The limit of SP-A detection was 0.16 ng/mL, and the assay limit was 500 ng/mL; the CV intra-assay value was 3.3%, and the CV interassay value was 10.2%.
Measurement of respiratory function
Forced spirometry was performed using a MasterLab apparatus (Jaeger, Würzburg, Germany), and static pulmonary volumes were measured using the plethysmography method. All the tests were performed following guidelines proposed by the European Respiratory Society (27) . Before each assessment, the procedure was demonstrated for the patient, who was asked to do some practice procedures. Subjects were required to perform a minimum of three reproducible measurements, and the output that produced the highest sum of FVC and FEV 1 values was chosen for the analysis. According to the Global Initiative for Chronic Obstructive Lung Disease, a normal FEV 1 is defined as a value $80% of predicted; a "nonobstructive ventilatory defect" is defined by an FVC ,80% of predicted value with an FEV 1 /FVC ratio .70%; an "obstructive ventilatory defect" is defined by an FEV 1 ,80% of the predicted value and FEV 1 /FVC ratio ,70% (28, 29) .
Statistical analysis
We evaluated the normality of the variables using the Kolmogorov-Smirnov test. Data were expressed as the arithmetic mean 6 standard deviation or percentage. Given their skewed distributions, serum SP-D and SP-A were expressed as the median (range) and the geometrical mean. Comparisons between groups were made using the Student t test and the Mann-Whitney U test for continuous variables and the x 2 test for categorical variables. For the remaining statistical analysis, serum SP-D and SP-A values were logarithmically transformed to achieve a normal distribution.
The relation between the continuous variables was assessed by the Pearson linear correlation test. The accuracy of SP-D as a measurement of interest to discriminate diseased cases (patients with FEV 1 ,80% of predicted) from normal cases was evaluated using a receiver operating characteristic (ROC) curve analysis and a complete sensitivity/specificity report. The total area under the ROC curve value was interpreted following the next guidelines: 0.9 to 1.0, excellent test; 0.8 to 0.9, good test; 0.7 to 0.8, fair test; 0.6 to 0.7, poor test, and 0.5 to 0.6, not useful.
To explore the variables that were independently associated with serum SP-D and a FEV 1 ,80% of predicted, stepwise multivariate regression analyses were used. The independent variables included in the analyses were age, BMI, sex, presence of T2D, HbA1c value, and the best cutoff value in terms of the sensitivity and specificity of SP-D obtained from the ROC analysis.
All P values were based on a two-sided test of statistical significance. Significance was accepted at the level of P , 0.05. Statistical analyses were performed using the SPSS statistical package (IBM SPSS Statistics for Windows, Version 20.0; Armonk, NY).
Results
Serum SP-D concentration was significantly higher in patients with T2D than in control subjects [133.0 (35.4 to 815.8) vs 97.6 (23.5 to 336.2) ng/mL; P = 0.006] (geometric means: 139.9 vs 99.4 ng/mL) (Fig. 1) . However, no ) than the control group without diabetes. In addition, a higher residual volume as well as a higher prevalence of ventilatory defects were detected in patients with T2D than in control subjects without diabetes.
When we evaluated the entire population in the univariate analysis, we noted a significant inverse correlation between serum SP-D and FEV 1 values (r = 20.265; P = 0.029), as well as a significant positive relation between SP-D and residual volume (r = 0.293; P = 0.043) ( Table 3) . Serum SP-A levels did not correlate with any of the pulmonary parameters. In addition, we did not observe any correlation between serum surfactant proteins and parameters of glycemic control (fasting plasma glucose and HbA1c values).
From the ROC analysis, the serum SP-D value itself was a good indicator for identifying patients with a FEV 1 ,80% of predicted. The best cutoff point for circulating SP-D (combining sensitivity plus specificity) was 123.2 ng/mL. At this value, the area under the curve was 0.725, the sensitivity was 77.7%, and the specificity was 69.4% (Fig. 2) . In fact, subjects with a serum SP-D concentration .132.3 ng/mL exhibited a significantly lower FEV 1 [87.2% 6 22.6% vs 98.1% 6 18.8% of predicted; mean difference 210.9 (95% confidence interval, 221.2 to 20.7); P = 0.035] and lower FEV 1 /FVC ratio [78.8 6 26.6 vs 92.2 6 13.4; mean difference 213.4 (95% confidence interval, 224.2 to 2.6); P = 0.016] compared with subjects with lower serum SP-D concentrations.
The stepwise multivariate regression analysis revealed that the presence of T2D and age, sex, and a serum SP-D concentration $132.3 ng/mL (but not HbA1c or BMI) were independently associated with a FEV 1 measurement ,80% of predicted (R 2 = 0.406). On the other hand, only the existence of T2D (but not age, BMI, HbA1c, sex, or FEV 1 ) was independently associated with serum SD-P concentration (R 2 = 0.138) (Table 4) .
Finally, when we compared patients with T2D with the group of obese subjects without diabetes but with similar decreased spirometric values [FEV 1 : 80.7% 6 10.7% of predicted; FVC: 80.8% 6 11.9% of predicted; FEF : 72.6% 6 30.0% of predicted; P = 0.697, P = 0.845, and P = 0.877, respectively], serum SP-D concentrations remained significantly higher in the former 
Discussion
We evaluated circulating surfactant proteins as biomarkers of lung injury in obese patients with T2D. We provide evidence that SP-D but not SP-A serum level increased in obese patients with T2D compared with obese control subjects without diabetes. In addition, a significant correlation between SP-D serum levels and functional parameters of lung impairment was found.
SP-D is a large, multimeric, collagenous glycoprotein formed by type II alveolar epithelial and Clara cells in the lungs (12) (13) (14) . In the alveolar epithelium, SP-D maintains lung immune homeostasis and removes apoptotic cells, allowing harmful inhaled pathogens to be cleared (12) . Its serum concentration has been evaluated in a variety of pulmonary diseases, and it has been proposed as a potential systemic biomarker for some lung diseases (20) . In addition, it is worth mentioning that elevated serum levels of SP-D have been found in nonpulmonary diseases that adversely affect the lungs as part of their systemic repercussions (30, 31) . Furthermore, circulating SP-D level could have a potential role as a prognostic factor. In this regard, an association between increased SP-D serum levels and risk of death in patients with acute lung injury, specifically lung cancer risk, has been reported (19, 32) . Notably, an opposite relationship between SP-D levels obtained in serum and in the fluid from bronchoalveolar lavage has been reported in COPD, thus supporting the concept that enhanced circulating levels of SP-D are related to increased transmigration of SP-D from the alveolar space into the blood (33, 34) .
The median level of serum SP-D herein reported in T2D was slightly higher than the higher upper limit found in healthy controls and was within the lower limit previously reported in patients with stable COPD (Supplemental Fig. 2 ). However, it was much lower than that observed in patients with either exacerbated COPD or pulmonary fibrosis (18, 20, 35) . Similarly, the magnitude of the median difference between our patients and controls (35.4 ng/mL) was similar to the difference noted between patients with COPD and healthy nonsmoking controls (38.1 ng/mL) in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study (18) . Therefore, in our group of patients without known lung disease and with well-established T2D, serum SP-D concentration may reflect mild pulmonary damage in the absence of clinical illness.
Several hypotheses have been proposed to explain the increase in peripheral circulation of SP-D associated with lung injury (20, 32) . However, the most plausible is based on the fact that SP-D is more hydrophilic than SP-A and that it escapes from the alveolar space into the vascular compartment because of changes in the alveolar epithelial permeability induced by low-grade chronic inflammation in lung parenchyma (32) . Supporting this hypothesis, treatment with systemic steroids induced a decrease in serum SP-D levels in subjects with COPD (20) .
Fernández-Real et al. (36) made the interesting hypothesis that innate lung immunity, as inferred from circulating SP-D concentrations, is at the crossroads of inflammation, obesity, and insulin resistance. In their study, lower rather than higher serum levels of SP-D were detected in patients with T2D compared with patients without diabetes. However, the selected T2D population was nonobese, and a substantial proportion of patients were diagnosed de novo with the 75-g oral glucose tolerance test. These different clinical features, in particular the longer duration of diabetes in patients included in our study, might explain the different results.
Our results also highlight one of the potential causes of the initiation and aggravation of pulmonary dysfunction in T2D. Although these pathophysiological mechanisms (i.e., insulin resistance, low-grade chronic inflammation, leptin resistance, microvascular damage, autonomic neuropathy) are usually described separately, each may explain a part of the whole picture, and many of them may act simultaneously (6) (7) (8) (9) . In addition, our finding that serum SP-D concentration was higher in patients with T2D than in subjects without diabetes but with similar lung functional impairment, points to bronchiolar surfactant layer dysfunction as a contributor to the impairment of airway caliber regulation that occurs in patients with T2D. Our data may help to identify patients with T2D for whom a respiratory function study is recommendable. When serum SP-D levels were evaluated in patients with various degrees of COPD, a significant inverse relationship between this biomarker and various lung function measurements was observed (20) (21) (22) (23) . These data were replicated in our study. In this regard, a negative correlation between FEV 1 , FVC, and FEF values and levels of serum SP-D was detected in obese patients with T2D. Therefore, measurement of serum SP-D concentration can be contemplated as a biomarker of lung impairment in obese patients with T2D, which could be useful as a first-step screening test. In our study, a value of 123.2 mg/mL was the best cutoff point to identify subjects with a FEV 1 ,80% of predicted. Patients with elevated SP-D concentrations could be candidates for further examination via respiratory function tests. Nevertheless, further studies and cost-effectiveness analyses aimed at examining the role of SP-D measurements in the clinical practice are needed.
We did not find any difference in serum SP-A concentrations between patients with T2D and healthy controls. These results agree with data from the National Heart, Lung, and Blood Institute ARDS (acute respiratory distress syndrome) Network trial, which revealed that baseline serum SP-A levels were not related to any clinical outcome (28) . However, more data are needed to rule out a possible relationship between SP-A value and lung impairment in T2D.
Our study was associated with some potential limitations. First, our investigation was a cross-sectional study; therefore, a causal link between T2D and serum SP-D level could not be established. Second, a decrease in renal clearance of surfactant proteins due to impaired glomerular filtration rate could account for the increased SP-D levels in patients with diabetes. However, the exclusion of patients with creatinine levels .1.4 mg/dL and the single increase of SP-D but not SP-A concentration make this possibility very unlikely. Finally, our study evaluated only a selected population of subjects with obesity, a condition not only associated with either a wide range of lung disorders or T2D but also with decreased levels of SP-D (18, 36) . Therefore, additional studies focusing on less-obese patients are required to better understand how defects in the bronchiolar surfactant layer affect the pulmonary function of patients with T2D.
Conclusion
We showed that serum SP-D concentrations were elevated in obese patients with T2D and that they were related to pulmonary function values. Therefore, circulating SP-D concentration seems to be a useful biomarker for testing lung involvement in obese patients with T2D. Additional studies are needed to examine whether serum SP-D concentration could be a reliable and cost-effective screening test for identifying patients with T2D who require a pulmonary function examination.
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